You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Pivotal trial of vamorolone in Duchenne muscular dystrophy

    SBC: ReveraGen BioPharma, Inc.            Topic: NINDS

    Abstract ReveraGen BioPharma is a clinical stage drug development company that is developing vamoroloneVBPa first in class dissociative steroidal drugThe initial indication being tested is Duchenne muscular dystrophyDMDwhere vamorolone holds promise for retaining or increasing efficacy of glucocorticoidswhile reducing adverse effectsbone fragilitystunting of growthweight gaininsulin resistanceReve ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  2. In Vitro Culture of Plasmodium falciparum Sporozoites for Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant Sanariaandapos s platform technology is production of aseptic purified cryopreserved Plasmodium falciparum Pf sporozoites SPZ This technology has produced three products administered by needle and syringe all of which are in clinical trials PfSPZ Vaccine radiation attenuated PfSPZ PfSPZ Challenge infectious PfSPZ for controlled human malaria infec ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  3. Genetically Attenuated PfSPZ Malaria Vaccine

    SBC: SANARIA INC.            Topic: R

    DESCRIPTION provided by applicant We build on the successful work in Phase II SBIR R AI in which a genetically attenuated Plasmodium falciparum Pf parasite GAP was produced and shown to generate aseptic Pf sporozoites SPZ that invade hepatocytes but do not replicate We will use this genetically attenuated double mutant parasite deficient in the genes encoding SLARP and B Pf ...

    SBIR Phase II 2015 Department of Health and Human ServicesNational Institutes of Health
  4. Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION provided by applicant The ideal tool for eliminating Plasmodium falciparum Pf the causative agent of of all malaria deaths would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission The only immunogens demonstrated in humans to be able to induce andgt protective efficacy that is sustained months are ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Plasmodium Falciparum Whole Sporozoite Malaria Vaccine

    SBC: SANARIA INC.            Topic: NIAID

    DESCRIPTION provided by applicant The ideal tool for eliminating Plasmodium falciparum Pf the causative agent of of all malaria deaths would be a highly effective vaccine that prevents blood stage infection and thereby prevents the disease and transmission The only immunogens demonstrated able to induce andgt sustained months protective efficacy in humans are Pf sporozoit ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. A Low Cost Integrated Method for Isolation of M. Tuberculosis DNA from Raw Sputum

    SBC: AKONNI BIOSYSTEMS INC.            Topic: NIAID

    Nucleic acid testing offers the potential to improve tuberculosis diagnosis world wideHigh purity DNA is essential to the success of virtually any downstream nucleic acid detection methodWe propose to develop a sample preparation system to extract and purify Mycobacterium tuberculosis DNA from raw sputumThe project goalas described in the solicitationPHSTopicis to develop an inexpensive and easy t ...

    SBIR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  7. Rapid Molecular Detection of Tuberculosis without PCR amplification

    SBC: SCANOGEN INC.            Topic: NIAID

    Project Summary TuberculosisTBis a major global burden that killsmillion people every yearTB mostly affects developing countriesbut the rise of multi drug and extensively drug resistant strains is a global threatIn order to control and eradicate this diseaseit is imperative to have adequate tools to detect active TB in limited resource settings and point of carePOCsettingswhich is where most TB pa ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  8. Phase IIa study of VBP for Duchenne muscular dystrophy

    SBC: ReveraGen BioPharma, Inc.            Topic: 106

    DESCRIPTION provided by applicant ReveraGen BioPharma is a clinical stage drug development company that is developing VBP a novel dissociative steroidal class drug The initial indication for development is Duchenne muscular dystrophy where VBP holds promise for retaining or increasing efficacy of glucocorticoids while reducing side effects bone fragilit stunting of growth VBP is c ...

    SBIR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
  9. Marketing Strategic Plan and Distribution Logistics for Sanaria PfSPZ Vaccine against Malaria.

    SBC: SANARIA INC.            Topic: NIAID

    ABSTRACT The development of Sanaria s Plasmodium falciparumPfsporozoiteSPZbased vaccines is receiving overwhelming global support after the publication inin Science of clinical data showingprotection against controlled human malaria infectionCHMIfollowing intravenous administration ofdoses of SanariaPfSPZ Vaccinecomposed of purifiedasepticradiation attenuatedcryopreserved PfSPZ meeting all regulat ...

    SBIR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health
  10. Automating mosquito microdissection for a malaria PfSPZ vaccine

    SBC: SANARIA INC.            Topic: R

    ABSTRACTThe global death toll from Malaria is estimated to be upwards ofpeople each yearwith more thanchildren succumbing every dayPlasmodium falciparumPfSporozoiteSPZbased vaccines are the only intervention in humansproven to induce robusthigh levelandgtand long lastingat leastmonthsprotective efficacy against malariaforming the basis of Sanaria s unique technology platform of asepticpurifiedcryo ...

    SBIR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government